World of DTC Marketing https://validator.w3.org/feed/docs/rss2.html Pharma’s Experience Problem: When “Yes” Becomes More Valuable Than Judgment Yale Single-Payer Health Study: Pros and Cons Heidi Overton Is the Wrong Choice for FDA Commissioner Pharma Marketers Are Measuring the Campaign—and Missing the Patient The Unsustainable Cost of Healthcare: A Voter’s Primary Concern No,Washington Won’t Ban Pharma TV Ads Should Employers Cover GLP-1 Drugs? The Answer Isn’t as Simple as Yes or No Medical Affairs Is Losing Its Way—and Pharma’s Hiring Practices Are Making It Worse Zenbexus: Is BMS Bringing the Future of Multiple Myeloma—or Revlimid 2.0—to a Market That Has Already Moved On? What Physicians Really Think About Big Pharma PR Releases On Prior Authorizations Don’t Tell A Story You Can Do Everything Right in America—and Cancer Can Still Bankrupt You Americans Agree Health Care Is Broken.. Does Pharma Care What GLP-1s Are Doing to Employer Healthcare Costs? Are Prescription Drug Prices Really Falling? Not So Fast. We’re Paying For Universal Healthcare Already How Do We Recognize the Patient-Centered Marketers in Pharma? AI Can Recommend the Treatment. But Who Owns the Decision? Why Is Pharma Still Making the Same Mistakes in Leadership and Hiring? Pharma’s Oncology Targeting Model Is Missing Part of the Care Team Pharma’s $5 Billion Question: What Value Does a Sales Representative Actually Add? The Best Way to Reach Physicians Online? Stop Trying to “Reach” Them. Why Are U.S. Hospital Costs Still Rising When Admissions Are Falling? FDA Enforcement Letters Should Be Required Reading for Every Pharma Marketer PhRMA Says Drug Spending Is “Stable.” The Data Tell a More Complicated Story. Pharma Is Spending Billions on New Drugs—Then Trying to Save Money on the People Who Explain the Science Did GLP-1 Clinical Trials Fail to Predict How Many Patients Would Quit? How Employers Can Control GLP-1 Costs Without Driving Employees to Quit If We Love Working in Pharma, Why Are We So Afraid to Speak Up About What’s Wrong With It? Medical Affairs Has a Leadership Problem Mark Cuban Didn’t Just Lower Drug Prices. He Exposed the Business Model. Some Drugs Shouldn’t Be Sold Between Commercial Breaks. Evenity Is One of Them. Novo Nordisk Didn’t Lose to a Better Drug. It Lost to a Faster Company If a Drug Has a Boxed Warning, It Shouldn’t Be Advertised on TV Health System Profits Are Increasingly Coming at the Expense of Patients Pharma Is Measuring SEO Wrong—and Wasting Money Because of It Pharma Is Losing Control of the Medical Answer America’s $5.7 Trillion Healthcare Bill: Progress, Warning—or Both? Does Pharma Have a Duty to Innovate? The Law Says No But.. Is the Pharma Industry Truly Patient-Centric? Examining the Silence Why Physician Loyalty Lies With MSLs, Not Companies Eli Lilly Expands Early Access to Retatrutide: Compassionate Care or PR Stunt? Validating Your Drug Launch Plan: Know When to Pivot While RFK Jr. Obsesses Over Food Dyes, Americans Are Getting Sick From Their Food When Pharma Experience Stops Being Valued by Pharma Companies Are Pharma CEOs Too Afraid to Give Patients Their Voices Back? If AstraZeneca Acquires Bristol Myers Squibb, BMS Employees Should Brace for Reality 60% of New Drug Launches Will Miss Expectations. Mismanaging Your MSL Team Could Be One Reason Why. PBMs Are Controlling The Market My Predictions for the GLP-1 Market